Abstract
We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
CTLA-4 Antigen / therapeutic use
-
Colitis / chemically induced
-
Colitis / immunology
-
Colitis / microbiology
-
Colitis / therapy*
-
Fecal Microbiota Transplantation / methods*
-
Female
-
Gastrointestinal Microbiome / drug effects*
-
Gastrointestinal Microbiome / immunology
-
Humans
-
Immune System / drug effects
-
Immune System / microbiology
-
Intestinal Mucosa / immunology
-
Intestinal Mucosa / microbiology
-
Intestinal Mucosa / pathology
-
Ipilimumab / adverse effects*
-
Male
-
Middle Aged
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
Programmed Cell Death 1 Receptor / therapeutic use
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / immunology
-
T-Lymphocytes, Regulatory / microbiology
Substances
-
CTLA-4 Antigen
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor